Sasanlimab

Generic Name: Sasanlimab

Clinical Trials

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Phase 2

Recruiting

Conditions: Urothelial Carcinoma Bladder

Interventions: Drug: Sasanlimab
Radiation: Stereotactic Body Radiation Therapy
Procedure: Radical Cystectomy + pelvic lymph node dissection + urinary diversion

First Posted Date: 2022-02-15

Last Posted Date: 2024-04-02

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 33

Registration Number: NCT05241340

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Sasanlimab Prefilled syringe
Drug: Sasanlimab
Drug: Encorafenib
Drug: Axitinib
Drug: SEA-TGT
Drug: Binimetinib

First Posted Date: 2020-10-14

Last Posted Date: 2024-12-17

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT04585815

Locations: 🇨🇳
Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States

and more 50 locations

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1

Active, not recruiting

Conditions: Neoplasm Metastasis

Interventions: Drug: PF-07265807
Drug: Sasanlimab
Drug: Axitinib

First Posted Date: 2020-07-07

Last Posted Date: 2024-04-03

Lead Sponsor: Pfizer

Target Recruit Count: 67

Registration Number: NCT04458259

Locations: 🇺🇸
Community Health Network Cancer Center North, Indianapolis, Indiana, United States
🇺🇸
Community Health Network Investigational Drug Services, Indianapolis, Indiana, United States
🇺🇸
Rocky Mountain Lions Eye Institute (RMLEI), Aurora, Colorado, United States

and more 52 locations

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer
Gastric Carcinoma
Gastroesophageal Junction Carcinoma
Classical Hodgkin Lymphoma
Diffuse Large B-cell Lymphoma
Peripheral T-cell Lymphoma
Cutaneous Melanoma
Head and Neck Squamous Cell Carcinoma
Bladder Cancer
Ovarian Cancer

Interventions: Drug: SEA-TGT
Drug: sasanlimab
Drug: brentuximab vedotin

First Posted Date: 2020-02-05

Last Posted Date: 2025-02-10

Lead Sponsor: Seagen Inc.

Target Recruit Count: 133

Registration Number: NCT04254107

Locations: 🇺🇸
California Research Institute, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States

and more 33 locations

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Phase 2

Active, not recruiting

Conditions: Non-small-cell Lung Cancer
Advanced Malignancies

Interventions: Drug: PF-06801591

First Posted Date: 2019-11-29

Last Posted Date: 2025-02-18

Lead Sponsor: Pfizer

Target Recruit Count: 155

Registration Number: NCT04181788

Locations: 🇨🇳
Beijing Cancer hospital, Beijing, Beijing, China
🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

and more 38 locations

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

Conditions: Non-muscle Invasive Bladder Cancer

Interventions: Drug: PF-06801591
Drug: Bacillus Calmette-Guerin

First Posted Date: 2019-11-15

Last Posted Date: 2025-01-15

Lead Sponsor: Pfizer

Target Recruit Count: 1070

Registration Number: NCT04165317

Locations: 🇺🇸
Chesapeake Regional Surgery Center - Virginia Beach, Virginia Beach, Virginia, United States
🇺🇸
Sulpizio Cardiovascular Center at UC San Diego Health, La Jolla, California, United States
🇺🇸
Urological Associates of Southern Arizona, P.C ., Tucson, Arizona, United States

and more 174 locations

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck
Melanoma Cancer
Gastric Cancer
Pancreatic Cancer
Esophageal Cancer
Bile Duct Cancer
Endometrial Cancer
Renal Cell Carcinoma
Lung Squamous Cell Carcinoma
Ovarian Cancer

Interventions: Drug: PF-06940434
Drug: PF-06801591

First Posted Date: 2019-11-05

Last Posted Date: 2025-02-04

Lead Sponsor: Pfizer

Target Recruit Count: 85

Registration Number: NCT04152018

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 28 locations

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

Phase 1

Completed

Conditions: Part 1
MELANOMA
SCCHN
SARCOMA
OVCA
OTHER SOLID TUMORS
Part 1 and 2
NSCLC
UROTHELIAL CARCINOMA

Interventions: Drug: PF-06801591

First Posted Date: 2015-10-09

Last Posted Date: 2021-12-13

Lead Sponsor: Pfizer

Target Recruit Count: 147

Registration Number: NCT02573259

Locations: 🇺🇦
Communal Non-profit Institution "City Clinical Hospital #4" of Dnipro City Council, Department of, Dnipro, Ukraine
🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Tennessee Oncology, PLLC, Smyrna, Tennessee, United States

and more 52 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy